A detailed history of Qube Research & Technologies LTD transactions in Immunic, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 174,961 shares of IMUX stock, worth $185,458. This represents 0.0% of its overall portfolio holdings.

Number of Shares
174,961
Previous 51 342960.78%
Holding current value
$185,458
Previous $0 Infinity%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.08 - $1.95 $188,902 - $341,074
174,910 Added 342960.78%
174,961 $288,000
Q2 2024

Aug 14, 2024

BUY
$0.98 - $1.44 $49 - $73
51 New
51 $0
Q3 2023

Nov 13, 2023

BUY
$1.35 - $2.87 $78 - $166
58 New
58 $0
Q3 2022

Nov 14, 2022

SELL
$3.0 - $5.49 $4,104 - $7,510
-1,368 Reduced 8.71%
14,342 $45,000
Q2 2022

Aug 15, 2022

BUY
$3.13 - $12.25 $49,172 - $192,447
15,710 New
15,710 $55,000

Others Institutions Holding IMUX

About IMMUNIC, INC.


  • Ticker IMUX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,565,000
  • Market Cap $32.4M
  • Description
  • Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...
More about IMUX
Track This Portfolio

Track Qube Research & Technologies LTD Portfolio

Follow Qube Research & Technologies LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.